BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush

Core Viewpoint - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is identified as one of the top 10 most shorted biotech stocks to consider for investment, with a price target increase from $21 to $22 by Wedbush analyst Laura Chico, who maintains an Outperform rating on the stock [1][2]. Financial Performance - For the fourth quarter, BioCryst reported an EPS of $1.12, a significant improvement from a loss of $0.13 in the same quarter of the previous year [3]. - The company achieved revenues of $406.5 million for the quarter, up from $131.5 million year-over-year [3]. Business Development - The CEO, Charlie Gayer, highlighted that 2025 was a transformative year for the company, marking its first full-year profitability driven by strong commercial execution and the highest level of new patient prescriptions for ORLADEYO since its launch [3]. - BioCryst completed the acquisition of Astria Therapeutics, which is expected to enhance its hereditary angioedema (HAE) portfolio and support long-term growth [3]. Product Pipeline - BioCryst focuses on developing treatments for rare and hard-to-treat diseases, with significant products aimed at managing influenza and hereditary angioedema [4]. - The company is also advancing several promising new medicines in clinical trials in collaboration with major pharmaceutical partners [4].